PriceTargets.com logo

Amedisys - AMED Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $100.67
  • Forecasted Upside: 19.17%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$84.47 As of 12/20/2024 06:15 PM ET
▲ +0.69 (0.82%)

This chart shows the closing price for AMED by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amedisys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMED

Analyst Price Target is $100.67
▲ +19.17% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Amedisys in the last 3 months. The average price target is $100.67, with a high forecast of $101.00 and a low forecast of $100.00. The average price target represents a 19.17% upside from the last price of $84.47.

This chart shows the closing price for AMED for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Amedisys. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/29/2024Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$101.00 ➝ $101.00
7/25/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$101.00 ➝ $101.00
7/1/2024William BlairDowngradeOutperform ➝ Market Perform
4/25/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$101.00
3/26/2024Raymond JamesReiterated RatingMarket Perform ➝ Market Perform
3/25/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$97.00 ➝ $100.00
9/14/2023Cantor FitzgeraldBoost TargetNeutral ➝ Neutral$100.00 ➝ $101.00
7/31/2023TD CowenBoost TargetMarket Perform ➝ Market Perform$84.00 ➝ $101.00
7/6/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
6/27/2023BenchmarkDowngradeBuy ➝ Hold
6/27/2023Truist FinancialBoost Target$97.00 ➝ $101.00
6/27/2023BarclaysBoost Target$88.00 ➝ $101.00
6/7/2023Truist FinancialDowngradeBuy ➝ Hold$97.00
6/6/2023Cantor FitzgeraldBoost Target$91.00 ➝ $100.00
6/6/2023Credit Suisse GroupDowngradeOutperform ➝ Neutral
5/5/2023SVB SecuritiesLower Target$96.00 ➝ $81.00
5/5/2023BarclaysLower Target$93.00 ➝ $88.00
5/4/2023Truist FinancialLower Target$115.00 ➝ $97.00
4/20/2023Cantor FitzgeraldInitiated CoverageNeutral$87.00
4/13/2023Truist FinancialLower TargetBuy$130.00 ➝ $115.00
3/14/2023StephensReiterated RatingEqual Weight$103.00
3/14/2023BenchmarkReiterated RatingBuy$115.00
3/13/2023BarclaysInitiated CoverageEqual Weight$93.00
2/27/2023Credit Suisse GroupReiterated RatingOutperform$115.00
2/21/2023Royal Bank of CanadaLower TargetOutperform$114.00 ➝ $111.00
2/16/2023StephensReiterated RatingEqual Weight$95.00
2/13/2023BenchmarkReiterated RatingBuy$120.00
1/25/2023BenchmarkLower TargetBuy$135.00 ➝ $120.00
1/23/2023Credit Suisse GroupLower TargetOutperform$140.00 ➝ $115.00
1/19/2023OppenheimerLower TargetOutperform$145.00 ➝ $125.00
1/5/2023Leerink PartnersLower TargetMarket Perform$96.00 ➝ $85.00
11/11/2022StephensLower TargetEqual Weight$122.00 ➝ $106.00
11/4/2022UBS GroupLower Target$88.00
11/4/2022CowenLower Target$103.00
11/2/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$150.00
11/1/2022Leerink PartnersLower TargetMarket Perform$116.00 ➝ $96.00
11/1/2022StephensBoost TargetEqual Weight$105.00 ➝ $122.00
10/31/2022Royal Bank of CanadaLower TargetOutperform$165.00 ➝ $139.00
10/28/2022BarclaysLower TargetOverweight$154.00 ➝ $126.00
10/28/2022StephensLower TargetEqual Weight$120.00 ➝ $105.00
10/28/2022Truist FinancialLower TargetBuy$140.00 ➝ $130.00
10/28/2022OppenheimerLower TargetOutperform$175.00 ➝ $145.00
10/27/2022Raymond JamesDowngradeOutperform ➝ Market Perform
10/24/2022Deutsche Bank AktiengesellschaftLower TargetBuy$175.00 ➝ $165.00
10/5/2022Truist FinancialLower TargetBuy$150.00 ➝ $140.00
10/3/2022BenchmarkLower TargetBuy$165.00 ➝ $135.00
8/9/2022CowenLower Target$125.00
8/2/2022UBS GroupDowngradeNeutral ➝ Sell$145.00 ➝ $95.00
7/29/2022Royal Bank of CanadaLower Target$199.00 ➝ $165.00
7/29/2022OppenheimerLower Target$200.00 ➝ $175.00
7/14/2022Truist FinancialLower TargetBuy$175.00 ➝ $150.00
6/28/2022Stifel NicolausInitiated CoverageHold$128.00
6/28/2022Jefferies Financial GroupReiterated RatingBuy$200.00
6/21/2022Leerink PartnersLower TargetMarket Perform$117.00 ➝ $107.00
6/21/2022Bank of AmericaDowngradeNeutral ➝ Underperform$145.00 ➝ $102.00
6/21/2022Deutsche Bank AktiengesellschaftLower TargetBuy$210.00 ➝ $175.00
6/21/2022Truist FinancialLower TargetBuy$200.00 ➝ $175.00
6/21/2022StephensLower TargetEqual Weight$155.00 ➝ $125.00
5/27/2022Leerink PartnersLower TargetMarket Perform$131.00 ➝ $117.00
4/29/2022OppenheimerReiterated RatingOutperform$200.00
4/29/2022Deutsche Bank AktiengesellschaftLower Target$230.00 ➝ $210.00
4/29/2022Raymond JamesLower Target$200.00 ➝ $180.00
4/7/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$200.00
3/1/2022UBS GroupUpgradeSell ➝ Neutral$152.00 ➝ $168.00
2/25/2022Royal Bank of CanadaLower TargetOutperform$221.00 ➝ $199.00
2/25/2022Credit Suisse GroupLower TargetOutperform$200.00 ➝ $195.00
2/25/2022Truist FinancialLower TargetBuy$210.00 ➝ $200.00
2/25/2022OppenheimerLower TargetOutperform$225.00 ➝ $200.00
2/25/2022Raymond JamesLower TargetOutperform$225.00 ➝ $200.00
2/25/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$210.00 ➝ $190.00
2/24/2022BenchmarkLower TargetBuy$200.00 ➝ $175.00
2/18/2022Leerink PartnersBoost TargetMarket Perform$145.00 ➝ $147.00
12/21/2021BarclaysLower TargetOverweight$236.00 ➝ $213.00
11/8/2021Raymond JamesLower TargetOutperform$250.00 ➝ $225.00
11/5/2021Deutsche Bank AktiengesellschaftLower TargetBuy$250.00 ➝ $230.00
11/4/2021StephensBoost TargetEqual Weight$178.00 ➝ $185.00
11/4/2021Royal Bank of CanadaLower TargetOutperform$244.00 ➝ $221.00
11/4/2021Credit Suisse GroupBoost TargetOutperform$192.00 ➝ $205.00
11/4/2021BMO Capital MarketsBoost TargetMarket Perform$180.00 ➝ $200.00
11/4/2021Leerink PartnersBoost TargetMarket Perform$170.00 ➝ $181.00
11/3/2021OppenheimerLower TargetOutperform$265.00 ➝ $225.00
10/13/2021Truist FinancialLower TargetBuy$255.00 ➝ $190.00
9/30/2021BMO Capital MarketsLower TargetNeutral ➝ Market Perform$240.00 ➝ $180.00
9/27/2021Leerink PartnersInitiated CoverageMarket Perform$170.00
9/23/2021UBS GroupInitiated CoverageSell$150.00
9/17/2021OppenheimerReiterated RatingBuy$265.00
9/9/2021CowenInitiated CoverageMarket Perform$195.00
8/11/2021Credit Suisse GroupLower TargetOutperform$330.00 ➝ $250.00
8/10/2021BenchmarkLower TargetBuy$325.00 ➝ $235.00
8/9/2021Raymond JamesLower TargetOutperform$325.00 ➝ $250.00
8/6/2021StephensLower TargetReduce ➝ Equal Weight$310.00 ➝ $237.00
8/6/2021OppenheimerLower TargetOutperform$325.00 ➝ $265.00
8/5/2021Bank of AmericaDowngradeBuy ➝ Neutral$220.00
4/30/2021Royal Bank of CanadaBoost TargetOutperform$335.00 ➝ $350.00
2/23/2021BenchmarkBoost TargetPositive ➝ Buy$275.00 ➝ $325.00
2/8/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$275.00 ➝ $340.00
1/5/2021Truist FinancialBoost Target$280.00 ➝ $325.00
11/3/2020BarclaysBoost TargetOverweight$290.00 ➝ $298.00
10/30/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$260.00 ➝ $275.00
10/30/2020Credit Suisse GroupBoost TargetOutperform$246.00 ➝ $280.00
9/21/2020OppenheimerBoost TargetOutperform$250.00 ➝ $260.00
9/10/2020StephensReiterated RatingEqual Weight$235.00 ➝ $245.00
9/2/2020BMO Capital MarketsBoost TargetMarket Perform$250.00 ➝ $270.00
8/20/2020BarclaysInitiated CoverageOverweight$290.00 ➝ $290.00
7/30/2020SunTrust BanksBoost TargetBuy$260.00 ➝ $270.00
7/30/2020BenchmarkBoost TargetBuy$210.00 ➝ $250.00
7/30/2020Royal Bank of CanadaBoost TargetOutperform$218.00 ➝ $260.00
7/30/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$220.00 ➝ $260.00
7/30/2020Raymond JamesBoost TargetOutperform$210.00 ➝ $255.00
7/29/2020Jefferies Financial GroupBoost TargetBuy$225.00 ➝ $250.00
7/10/2020SunTrust BanksBoost TargetBuy$240.00 ➝ $260.00
6/18/2020BenchmarkUpgradeHold ➝ Buy$210.00
5/21/2020SunTrust BanksBoost TargetBuy$225.00 ➝ $240.00
5/11/2020UBS GroupLower TargetNeutral$208.00 ➝ $190.00
5/11/2020Raymond JamesLower TargetOutperform$225.00 ➝ $210.00
5/10/2020Royal Bank of CanadaReiterated RatingBuy$218.00
5/7/2020BenchmarkDowngradeBuy ➝ Hold
4/27/2020OppenheimerReiterated RatingBuy$215.00
3/9/2020BenchmarkUpgradeHold ➝ Buy$205.00
2/21/2020StephensBoost TargetEqual Weight$180.00 ➝ $200.00
2/21/2020UBS GroupBoost TargetNeutral$154.00 ➝ $208.00
2/21/2020BMO Capital MarketsReiterated RatingMarket Perform$215.00
2/21/2020Credit Suisse GroupBoost TargetOutperform$206.00 ➝ $214.00
2/20/2020SunTrust BanksBoost TargetBuy$185.00 ➝ $225.00
2/20/2020Raymond JamesBoost TargetOutperform$200.00 ➝ $225.00
1/17/2020Credit Suisse GroupInitiated CoverageOutperform$206.00
1/3/2020Raymond JamesSet TargetOutperform$144.00 ➝ $200.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 13 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 9 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 11 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 12 very positive mentions
  • 11 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 17 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 17 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Amedisys logo
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Read More

Today's Range

Now: $84.47
Low: $82.15
High: $84.87

50 Day Range

MA: $91.75
Low: $83.78
High: $97.71

52 Week Range

Now: $84.47
Low: $82.15
High: $98.95

Volume

2,375,039 shs

Average Volume

385,018 shs

Market Capitalization

$2.77 billion

P/E Ratio

33.52

Dividend Yield

N/A

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Amedisys?

The following Wall Street sell-side analysts have issued reports on Amedisys in the last year: Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Raymond James, Royal Bank of Canada, StockNews.com, and William Blair.
View the latest analyst ratings for AMED.

What is the current price target for Amedisys?

0 Wall Street analysts have set twelve-month price targets for Amedisys in the last year. Their average twelve-month price target is $100.67, suggesting a possible upside of 19.2%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting AMED will reach $101.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $100.00 for Amedisys in the next year.
View the latest price targets for AMED.

What is the current consensus analyst rating for Amedisys?

Amedisys currently has 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AMED, but not buy more shares or sell existing shares.
View the latest ratings for AMED.

What other companies compete with Amedisys?

Other companies that are similar to Amedisys include Chemed, CorVel, R1 RCM, Pediatrix Medical Group and AMN Healthcare Services. Learn More about companies similar to Amedisys.

How do I contact Amedisys' investor relations team?

Amedisys' physical mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider's listed phone number is (225) 292-2031 and its investor relations email address is [email protected]. The official website for Amedisys is www.amedisys.com. Learn More about contacing Amedisys investor relations.